{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:23Z","timestamp":1793339183927,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["VIA083"],"award-info":[{"award-number":["VIA083"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["RECOVER01"],"award-info":[{"award-number":["RECOVER01"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023551","name":"Cystic Fibrosis Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["VIA083"],"award-info":[{"award-number":["VIA083"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["RECOVER01"],"award-info":[{"award-number":["RECOVER01"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Clinical trials have shown that use of elexacaftor\/tezacaftor\/ivacaftor (ETI) is associated with improvements in sweat chloride, pulmonary function, nutrition, and quality of life in people with cystic fibrosis (CF). Little is known about the impact of ETI on ventilation inhomogeneity and lung structure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>RECOVER is a real-world study designed to measure the impact of ETI in people with CF. The primary endpoints were lung clearance (lung clearance index; LCI2.5) and FEV1. Secondary endpoints included spirometry-controlled chest computed tomography (CT) scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was conducted in seven sites in Ireland and the United Kingdom. Participants ages 12\u2009years and older who were homozygous for the F508del mutation (F508del\/F508del) or heterozygous for F508del and a minimum-function mutation (F508del\/MF) were recruited before starting ETI and were followed up over 12 months. LCI2.5 was measured using nitrogen multiple breath washout (MBW) at baseline and at 6 and 12 months. Spirometry was performed as per the criteria of the American Thoracic Society and the European Respiratory Society. Spirometry-controlled chest CT scans were performed at baseline and at 12 months. CT scans were scored using the Perth Rotterdam Annotated Grid Morphometric Analysis (PRAGMA) system. Other outcome measures include weight, height, Cystic Fibrosis Quality of Life Questionnaire\u2014Revised (CFQ-R), and sweat chloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>One hundred seventeen people with CF ages 12 and older were recruited to the study. Significant improvements were seen in LCI scores (\u22122.5; 95% confidence interval [CI], \u22123.0, \u22122.0) and in the percents predicted for FEV1 (8.9; 95% CI, 7.0, 10.9), FVC (6.6; 95% CI, 4.9, 8.3), and forced expiratory flow between 25% and 75% of expired volume (12.4; 95% CI, 7.8, 17.0). Overall PRAGMA-CF scores reflecting airway disease improved significantly (\u22123.46; 95% CI, \u22125.23, \u22121.69). Scores for trapped air, mucus plugging, and bronchial wall thickening improved significantly, but bronchiectasis scores did not. Sweat chloride levels decreased in both F508del\/F508del (\u221243.1; 95% CI, \u221247.4, \u221238.9) and F508del\/MF (\u221242.8; 95% CI, \u221248.5, \u221237.2) groups. Scores on the Respiratory Domain of the CFQ-R improved by 14.2 points (95% CI, 11.3, 17.2). At 1\u2009year, sweat chloride levels were significantly lower for the F508del\/F508del group compared with scores for the F508del\/MF group (33.93 vs. 53.36, P\u2009&amp;lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ETI is associated with substantial improvements in LCI2.5, spirometry, and PRAGMA-CF CT scores in people with CF ages 12\u2009years and older. ETI led to improved nutrition and quality of life. People in the F508del\/F508del group had significantly lower sweat chloride on ETI treatment compared with the F508del\/MF group.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 04602468).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202308-1317oc","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:48:45Z","timestamp":1694605725000},"page":"917-929","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":96,"title":["Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older \u2013 The RECOVER Trial"],"prefix":"10.1093","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-1712","authenticated-orcid":false,"given":"Paul","family":"McNally","sequence":"first","affiliation":[{"name":"Department of Pediatrics, RCSI University of Medicine and Health Sciences, Dublin, Ireland"},{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, RCSI University of Medicine and Health Sciences, Dublin, Ireland"},{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, RCSI University of Medicine and Health Sciences, Dublin, Ireland"},{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Elnazir","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Williamson","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Des","family":"Cox","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Linnane","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Limerick, Limerick, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kirwan","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Registry of Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rea","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O\u2019Regan","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Registry of Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Semple","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Saunders","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm A.W.M.","family":"Tiddens","sequence":"additional","affiliation":[{"name":"Erasmus Medical Centre, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-8208","authenticated-orcid":false,"given":"Edward","family":"McKone","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital, Dublin, Ireland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, United Kingdom"},{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"2026012204344443400_bib1","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012204344443400_bib2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012204344443400_bib3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012204344443400_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012204344443400_bib5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026012204344443400_bib6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacftor\/ivacaftor in people with cystic fibrosis","volume":"205","author":"Nichols","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"key":"2026012204344443400_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jcf.2019.09.001","article-title":"Guidance for computed tomography (CT) imaging of the lungs for patients with cystic fibrosis (CF) in research studies","volume":"19","author":"van Straten","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012204344443400_bib11","doi-asserted-by":"crossref","first-page":"1318027","DOI":"10.1080\/20018525.2017.1318027","article-title":"Association between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosis","volume":"4","author":"Kongstad","year":"2017","journal-title":"Eur Clin Respir J"},{"key":"2026012204344443400_bib12","doi-asserted-by":"crossref","first-page":"e0240898","DOI":"10.1371\/journal.pone.0240898","article-title":"Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study","volume":"15","author":"Tiddens","year":"2020","journal-title":"PLoS One"},{"key":"2026012204344443400_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single-breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"key":"2026012204344443400_bib14","doi-asserted-by":"crossref","first-page":"e0157523","DOI":"10.1371\/journal.pone.0157523","article-title":"A systematic approach to multiple breath nitrogen washout test quality","volume":"11","author":"Jensen","year":"2016","journal-title":"PLoS One"},{"key":"2026012204344443400_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ppul.23490","article-title":"Spirometer guided chest imaging in children: it is worth the effort!","volume":"52","author":"Salamon","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2026012204344443400_bib16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1164\/rccm.201501-0061OC","article-title":"PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis","volume":"191","author":"Rosenow","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis \u2013 a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012204344443400_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jcf.2020.10.007","article-title":"Utility of lung clearance index in CF: what we know, what we don\u2019t know and musings on how to bridge the gap","volume":"19","author":"Short","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012204344443400_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12931-023-02497-0","article-title":"The clinical impact of lumacaftor-ivacaftor on structural lung disease and lung function in children aged 6\u201311 with cystic fibrosis in a real-world setting","volume":"24","author":"McNally","year":"2023","journal-title":"Respir Res"},{"key":"2026012204344443400_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1183\/13993003.01918-2015","article-title":"Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor","volume":"48","author":"Chassagnon","year":"2016","journal-title":"Eur Respir J"},{"key":"2026012204344443400_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.201308-1433IM","article-title":"Ivacaftor imaging response in cystic fibrosis","volume":"189","author":"Hoare","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chest.2017.10.005","article-title":"CORK Study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor","volume":"153","author":"Ronan","year":"2018","journal-title":"Chest"},{"key":"2026012204344443400_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcf.2014.06.011","article-title":"Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation","volume":"14","author":"Sheikh","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026012204344443400_bib25","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/jcm10091999","article-title":"Computed tomographic changes in patients with cystic fibrosis treated by combination therapy with lumacaftor and ivacaftor","volume":"10","author":"Arnaud","year":"2021","journal-title":"J Clin Med"},{"key":"2026012204344443400_bib26","doi-asserted-by":"crossref","first-page":"2101344","DOI":"10.1183\/13993003.01344-2021","article-title":"Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis","author":"Campredon","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012204344443400_bib27","doi-asserted-by":"crossref","first-page":"2100844","DOI":"10.1183\/13993003.00844-2021","article-title":"Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators","volume":"59","author":"Dournes","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204344443400_bib28","doi-asserted-by":"crossref","first-page":"110421","DOI":"10.1016\/j.ejrad.2022.110421","article-title":"Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: early report","volume":"154","author":"Bec","year":"2022","journal-title":"Eur J Radiol"},{"key":"2026012204344443400_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204344443400_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026012204344443400_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","article-title":"Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype","volume":"14","author":"McKone","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026012204344443400_bib32","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ppul.26430","article-title":"Reply to migration is not the perfect answer: optimized methodology to assess LCI agreement between corrected legacy multiple breath nitrogen washout data and that directly collected on updated software","volume":"58","author":"De Queiroz Andrade","year":"2023","journal-title":"Pediatr Pulmonol"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/208\/9\/917\/66426726\/ajrccm_208_9_917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/208\/9\/917\/66426726\/ajrccm_208_9_917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:34:52Z","timestamp":1769074492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/208\/9\/917\/8426759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202308-1317oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"2023-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}